To clarify the effects of long-term treatments with weight reduction (WR), ACE inhibitor (ACEI; enalapril) and angiotensin II antagonist (AIIA; candesartan) in obese hypertensives on BP reduction, especially focusing on sympathetic activity, renin angiotensin system (RAS), plasma insulin (INS) and leptin (LEP). Five groups with 20 obese hypertensives (HT) each were treated with WR alone, ACEI alone, AIIA alone, ACEIϩWR, AIIAϩWR over 12 months. WR was defined as 10% or more reduction in BMI for the first 6 months. The doses of ACEI and AIIA were chosen as less than 140/90 mmHg. At entry, month 6 & 12, BMI, BP, pulse rate (PR), plasma norepinephrine (NE), PRA, AII, INS and LEP were measured after overnight fast. WR program was performed in low caloric diet (1000 kcal, NaCl 7g/day) and exercise. At month 6, WR was succeeded in 65% of WR alone group, 60% of ACEIϩWR, and 50% of AIIAϩWR. BP and NE were suppressed in 5 groups at month 6. PRA and AII increased in AIIA alone group, although those decreased in the other 4 groups. At month 6 & 12, BP was lower in order of ACEIϩWR Ͻ AIIAϩWR Ͻ ACEI alone Ͻ AIIA alone Ͻ WR. Plasma NE and PR were lower in order of ACEIϩWR Ͻ ACEI alone Ͻ AIIAϩWR Ͻ AIIA alone Ͻ WR. AII was lower in order of ACEIϩWR Ͻ ACEI alone Ͻ WR Ͻ AIIAϩWR Ͻ AII alone. Plasma INS and LEP were lower in AIIAϩWR Ͻ ACEIϩWR Ͻ WR Ͻ AIIA alone Ͻ ACEI alone. In a whole cohort, at month 6 and 12 the reduction in plasma AII (⌬AII) correlated with ⌬NE (PϽ0.01 at month 6, PϽ0.05 at month 12) and ⌬leptin (PϽ0.05 at month 6, PϽ0.05 at month 12). In addition, ⌬insulin correlated with ⌬leptin (PϽ0.05 at month 6, PϽ0.01 at month 12). These results demonstrate that both pharmacological therapies with ACEI & AIIA with WR suppressed sympathetic hyperactivity and activated RAS in obesity hypertension. Despite the fact that BP reduction with WR alone is less than achieved by drugs, weight reduction should be regarded as an essential component of treatment program for obesity hypertension, because of the favorable metabolic responses. Plasma leptin level appears to be regulated by plasma insulin and AII without bradykinin or angiotensin converting enzyme pathways.
We have shown that trandolapril-verapamil (TV) reduces proteinuria in diabetic hypertensive patients (DHP) insufficiently pretreated with an angiotensin converting-enzyme (ACE) inhibitor, even though a group of those patients did not reach an adecuate glycemic control. The aim of this work is to evaluate the effect of TV on proteinuria in a cohort of those DH patients that did not reached a good glycemic control.
We include DH patients with blood pressure Ͼ 140/90 mm Hg in spite of more than 6 month of treatment with an ACE inhibitor. They received TV (2/180 mg in the same pill) once a day. In all of them blood pressure was registered monthly (in triplicate), as well as fasting serum glucose. Also 24 hrs proteinuria was determinated at the beggining of the study and six month later, good glycemic control was defined as fasting serum glucose Ͻ 140 mg/dl. Statistical analysis was performed with ANOVA. We found that 30 patients did not reach a good metabolic control during the study, They has a blood pressure reduction from 168Ϯ5/ 93Ϯ3 to 135Ϯ4/79Ϯ5 mm Hg (pϽ 0,001). 24 hours proteinuria went down from 4564.7 to 2096.9 mg, (pϽ0.01). three patients suffered symptomatic hypotension and were controlled with half of the dose, we did not find significative changes in heart rate (76Ϯ6 to 75Ϯ5 bpm pϾ0.05). We conclude that TV is effective in reducing proteinuria in DH patients insufficiently pretreated with an ACE inhibitor, even in the case of a poor glycemic control, this fact may be relevant in the renoprotection on DH patients. Mora, J. Rodriguez, C. Campos, F.J. Aranda, M. López, I. Martinez, M. Luque. Spanish Hypertension Society. Madrid. Spain In a nation-wide survey 367 treated essential hypertensive men (mean time since diagnosis: 8,4Ϯ4,5 years and mean age: 52,7Ϯ8 years) were interviewed about their sexual health by filling up the Sexual Health Index for Men (SHIM) form. They had as associated CV risk factors (%): diabetes (35,97); dyslipidemie (27,2) or smoking (11, 4) , and as CV complications (%) IHD (9,2), Stroke (2.5) or CRF (15). After answering the 5 questions about their sexual activity, the
